Financing ·
Celularity raises $11M via senior secured convertible notes and settles debt disputes by issuing shares
CELUCelularity Inc
Celularity Inc. entered into a Securities Purchase Agreement to issue up to $25.0 million in senior secured convertible promissory notes with warrants. At the initial closing on September 24, 2026, the company raised approximately $11.01 million by issuing notes convertible at $1.50 per share into roughly 7,340,000 shares, alongside warrants for approximately 4,037,000 additional shares. The transaction includes a second tranche of up to $10.0 million available through September 2027 and amends existing debt held by the Philip & Daniele Barach Family Trust. Concurrently, Celularity settled disputes with Helena Global Investment Opportunities 1 Ltd by converting $1.197 million in principal into 700,000 shares and issuing an additional 2,000,000 shares of common stock as settlement consideration. Effective September 24, 2026, Geoffrey Ling resigned from the Board, and Philip A. Barach was appointed to replace him pursuant to a board rights agreement associated with the financing. Celularity Inc. operates in the biotechnology industry, focusing on cellular therapies for regenerative medicine.